AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 217 filers reported holding AMICUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,118,998 | -0.4% | 1,078,865 | +2.9% | 0.83% | +11.4% |
| Q2 2023 | $13,171,201 | +40.2% | 1,048,663 | +23.8% | 0.75% | +40.1% |
| Q1 2023 | $9,391,666 | +8.7% | 846,859 | +19.6% | 0.53% | +7.7% |
| Q4 2022 | $8,643,312 | +15.9% | 707,888 | -0.9% | 0.50% | +14.8% |
| Q3 2022 | $7,458,000 | -24.0% | 714,409 | -21.9% | 0.43% | -9.1% |
| Q2 2022 | $9,819,000 | +64.7% | 914,275 | +45.2% | 0.48% | +99.6% |
| Q1 2022 | $5,962,000 | -16.1% | 629,617 | +2.3% | 0.24% | -5.6% |
| Q4 2021 | $7,106,000 | +15.0% | 615,197 | -4.9% | 0.25% | +10.5% |
| Q3 2021 | $6,178,000 | -1.5% | 646,898 | -0.6% | 0.23% | +2.2% |
| Q2 2021 | $6,272,000 | -19.8% | 650,620 | -17.8% | 0.22% | -12.5% |
| Q1 2021 | $7,819,000 | -42.9% | 791,367 | +33.6% | 0.26% | -47.0% |
| Q4 2020 | $13,682,000 | – | 592,532 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |